<DOC>
	<DOCNO>NCT01024192</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy safety use Stilnox CR Mexican patient chronic insomnia prescription condition daily practice Secondary Objective : To evaluate satisfaction patient chronic insomnia Stilnox CR need basis .</brief_summary>
	<brief_title>Efficacy Safety Assessment ZOlpidem ( Stilnox CR ) Patients With Chronic insomNIA</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Primary insomnia diagnosis ( difficulty initiate sleep , maintain sleep wake early morning , present restless sleep ) cause clinically significant disturbance area social , work function important area Exclusion criterion : Serious , severe and/or acute respiratory impairment Severe liver impairment Hypersensitivity formulation component active metabolite Pregnant breastfeed woman Patients important associate disorder SNC specially psychotic disorder Patients probability use alcoholic beverage concomitantly ( precaution measure ) Chronic use benzodiazepine Moreover , order follow international regulation term use handle hypnotic compound , guarantee appropriate study performance , patient one follow characteristic include : Patients comply followup Patients drug abuse problem Individuals work change night shift pathological snore Presence ( suspicion ) sleep apnea , periodical leg movement restless legs syndrome The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>